Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
City of Hope Medical Center
Eli Lilly and Company
Pfizer
Johnson & Johnson Enterprise Innovation Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Genmab
Astellas Pharma Inc
Coherus Oncology, Inc.
R-Pharm
Pfizer
University of Maryland, Baltimore
AstraZeneca
University of Vermont
Washington University School of Medicine
University of Oxford
Children's Oncology Group
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HonorHealth Research Institute
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim
Boehringer Ingelheim
University of Maryland, Baltimore
InSilico Medicine Hong Kong Limited
Fate Therapeutics
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
AstraZeneca
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
University of Southern California
National Cancer Institute (NCI)
University of Vermont
Tesaro, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
AbbVie
Merck Sharp & Dohme LLC
Sanford Health
Merck Sharp & Dohme LLC
EMD Serono
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center